HONG KONG – South Korea's Alteogen Inc.'s trastuzumab-based antibody-drug conjugate (ADC), ALT-P7, might face heavy competition in the breast cancer space, but the drug gained a potential leg up in gastric cancer, with the FDA awarding orphan designation.

HONG KONG – China purged about 40 provincial and local officials, including top staff of China's drug watchdog, after a meeting of the Politburo Standing Committee, led by President Xi Jinping, who pledged to punish rabies vaccine maker Changchun Changsheng Bio-technology Co., of Jilin Province, for stirring up fears for public health.

HONG KONG – South Korea's Alteogen Inc.'s trastuzumab-based antibody-drug conjugate (ADC), ALT-P7, might face heavy competition in the breast cancer space, but the drug gained a potential leg up in gastric cancer, with the FDA awarding orphan designation.

HONG KONG – In a $120 million deal focused on the greater China region, Glenmark Pharmaceuticals Ltd. joined hands with China's Harbour Biomed Therapeutics Ltd. to co-develop the U.S. company's bispecific antibody (bsAb), GBR-1302, for treating HER2-positive cancers, including breast, gastric and ovarian cancers.

HONG KONG – In a $120 million deal focused on the greater China region, Glenmark Pharmaceuticals Ltd. joined hands with China's Harbour Biomed Therapeutics Ltd. to co-develop the U.S. company's bispecific antibody (bsAb), GBR-1302, for treating HER2-positive cancers, including breast, gastric and ovarian cancers.

HONG KONG – South Korea's Samyang Biopharmaceutical Corp. is set to expand to the U.S. with a new office in Boston, scheduled to open this month. The new location will focus on biologics product development as well as leveraging the local network for M&A opportunities.